CLINICAL_TRIALS
withdrawal
· 2012-05-28
Clinical Trial Update: A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease [Phase 3]
Summary
A Phase 3 trial evaluating the safety of chronic therapy with certolizumab pegol in Crohn's disease has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: UCB Pharma | Conditions: Crohn's Disease | Phase 3 | Status: WITHDRAWN